HUTCHMED - 2025 Annual Report and Notice of Annual General Meeting

HUTCHMED (China) Limited

和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on April 9, 2026.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, April 9, 2026

As at the date of this announcement, the Directors of the Company are:

Chairman and Non-executive Director: Non-executive Directors:

Dr Dan ELDAR Ms Edith SHIH

Ms Ling YANG

Executive Directors:

Dr Weiguo SU Independent Non-executive Directors: (Chief Executive Officer and Professor MOK Shu Kam, Tony

Chief Scientific Officer) (Senior and Lead Independent Non-executive Director) Mr CHENG Chig Fung, Johnny Dr Renu BHATIA

(Acting Chief Executive Officer and Dr Chaohong HU

Chief Financial Officer) Professor TAN Shao Weng, Daniel

Mr WONG Tak Wai

2025 Annual Report and Notice of Annual General Meeting

Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 9, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2025 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials"), will be posted on April 10, 2026 to those shareholders who have elected to receive the AGM Materials in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com).

The 2026 Annual General Meeting ("AGM") will be an electronic/hybrid meeting to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong on Tuesday, May 12, 2026 at 4:00 pm Hong Kong Time (9:00 am London Time), with electronic access through an online platform as detailed in the AGM Materials.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries +852 2121 8200 / [email protected]

Media Enquiries

FTI Consulting – +44 20 3727 1030 / [email protected]

Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7779 436 689 (Mobile)

Brunswick – Zhou Yi +852 9783 6894 (Mobile) / [email protected]

Panmure Liberum Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500

Cavendish Joint Broker

Geoff Nash / Nigel Birks +44 20 7220 0500

Deutsche Numis Joint Broker

Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000